Bijina Balakrishnan | Molecular Basis of Genetic Disease | Best Researcher Award

Posted on by PencisLeave a Comment on Bijina Balakrishnan | Molecular Basis of Genetic Disease | Best Researcher Award

Dr. Bijina Balakrishnan | Molecular Basis of Genetic Disease | Best Researcher Award

University of Utah | United States

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Bijina Balakrishnan embarked on her academic journey in the field of biotechnology with a Bachelor of Science degree in Biology & Chemistry from the University of Calicut, Kerala, India, in 1999. She further pursued her passion for biotechnology by obtaining a Master of Science degree in Biotechnology from Cochin University of Science and Technology, Kerala, India, in 2002. Her dedication to advancing knowledge in the field led her to pursue a Doctor of Philosophy (PhD) in Biotechnology, which she successfully completed at Cochin University of Science and Technology, Kerala, India, in 2008.

PROFESSIONAL ENDEAVORS

Balakrishnan's professional journey has been characterized by a steadfast commitment to research excellence and innovation. She has held various significant positions in esteemed academic and research institutions, including:

RESEARCH SCIENTIST University of Utah, Salt Lake City (2021 - Present)

RESEARCH ASSOCIATE University of Utah, Salt Lake City (2019 - 2021)

POST-DOCTORAL FELLOW University of Utah, Salt Lake City (2014 - 2019)

POST-DOCTORAL FELLOW Nanyang Technological University, Singapore (2008)

SENIOR RESEARCH FELLOW Kannur University, India (2007 - 2008)

GRADUATE RESEARCHER Cochin University of Science and Technology, India (2003 - 2007)

CONTRIBUTIONS AND RESEARCH FOCUS ON MOLECULAR BASIS OF GENETICS DISEASE

Balakrishnan's contributions to the field of biotechnology are multifaceted and impactful, spanning from basic research to translational applications. Her research endeavors have primarily focused on rare metabolic disorders, with a particular emphasis on Galactosemia and dilated cardiomyopathy. Some notable contributions include:

  • Development and optimization of preclinical therapeutic interventions for Galactosemia and dilated cardiomyopathy.
  • Characterization of mouse models for Galactosemia and elucidation of disease mechanisms.
  • Design and execution of gene therapy strategies for cardiac-specific conditions.
  • Profiling small molecule modulators for novel therapeutic targets.
  • Investigation of cellular responses to viral proteins, such as the SARS-CoV-2 Spike protein, and evaluation of potential therapeutic interventions.

IMPACT AND INFLUENCE

Balakrishnan's work has made a significant impact on both the scientific community and the broader field of biotechnology. Her research findings have been presented at numerous conferences and workshops, contributing to the dissemination of knowledge and fostering collaboration among scientists. Additionally, her efforts have led to the development of novel therapeutic approaches for rare metabolic disorders, offering hope to patients and clinicians alike.

ACADEMIC CITATIONS

Balakrishnan's research contributions have been recognized through academic honors and awards, including the Best Researcher Award at the International Research Awards on Cardiology and Cardiovascular Medicine. Moreover, she has received prestigious grants and funding support from organizations such as the Galactosemia Foundation and the National Institutes of Health (NIH).

LEGACY AND FUTURE CONTRIBUTIONS

Balakrishnan's legacy in the field of biotechnology is characterized by her dedication to scientific inquiry, innovation, and translational research. As she continues her professional journey, she remains committed to advancing knowledge, developing novel therapeutic interventions, and mentoring the next generation of scientists. Her future contributions are poised to further shape the landscape of biotechnology and positively impact the lives of individuals affected by rare metabolic disorders.

NOTABLE PUBLICATIONS

Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia 2020(38)

Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors 2021(3)

AAV-based gene therapy prevents and halts the progression of dilated cardiomyopathy in a mouse model of phosphoglucomutase 1 deficiency (PGM1-CDG) 2023(3)

AAV9-based PMM2 gene replacement augments PMM2 expression and improves glycosylation in primary fibroblasts of patients with phosphomannomutase 2 deficiency (PMM2-CDG)

Whole-body galactose oxidation as a robust functional assay to assess the efficacy of gene-based therapies in a mouse model of Galactosemia

Laura Warmke | Pathology | Best Researcher Award

Posted on by PencisLeave a Comment on Laura Warmke | Pathology | Best Researcher Award

Dr. Laura Warmke | Pathology | Best Researcher Award

University of Indiana School of Medicine | United States

Author Profile

Orcid ID

EARLY ACADEMIC PURSUITS:

During my undergraduate years from 2005 to 2009 at the University of Virginia, I pursued a Bachelor of Science in Chemistry with Distinction, accompanied by a Minor in Studio Art. This foundational period laid the groundwork for my multifaceted approach to learning, blending the analytical rigor of the sciences with the creative elements of studio art.

PROFESSIONAL ENDEAVORS:

In 2010, I embarked on the journey towards a Doctor of Medicine (M.D.) degree at the Virginia Commonwealth University School of Medicine in Richmond, VA. This phase of my education marked the transition from theoretical knowledge to the practical application of medical expertise, fostering my commitment to the field of pathology.

CONTRIBUTIONS AND RESEARCH FOCUS ON PATHOLOGY:

Throughout my residency at Virginia Commonwealth University Health System (2014-2017), I actively engaged in the field of Anatomic Pathology/Clinical Pathology (AP/CP), developing a keen interest in bone and soft tissue pathology. This interest led me to pursue specialized training, culminating in my Selective Bone & Soft Tissue Pathology Fellowship at The University of Texas MD Anderson Cancer Center in Houston, TX (2019-2020).

IMPACT AND INFLUENCE:

My role as the AP/CP Pathology Chief Resident at Virginia Commonwealth University Health System (2017-2018) allowed me to contribute significantly to the department's operations. I played a pivotal role in bridging clinical and anatomical aspects, fostering a comprehensive understanding of pathology.

ACADEMIC CITES:

In 2018, I achieved board certification in Anatomic Pathology/Clinical Pathology (AP/CP) from the American Board of Pathology, affirming my proficiency and dedication to maintaining the highest standards in the field.

LEGACY AND FUTURE CONTRIBUTIONS:

Since 2020, I have served as an Assistant Professor of Clinical Pathology & Laboratory Medicine at Indiana University School of Medicine. In this capacity, I continue to impart knowledge, mentor future pathologists, and contribute to the advancement of pathology through my clinical work and research endeavors.

HIGHLIGHTS:

My commitment to excellence is underscored by my continuous pursuit of knowledge and certifications, including my current Indiana Medical License (expiring 10/31/2025) and my status as a Basic Life Support (BLS) Provider certified by the American Heart Association.

FUTURE CONTRIBUTIONS:

Looking ahead, I am dedicated to furthering research, education, and patient care in the realm of pathology. I aspire to make enduring contributions to the field, leaving a lasting legacy through my dedication to excellence, mentorship, and continued pursuit of knowledge.

Notable publications:

Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma 2022(1)

“PRRX1-rearranged mesenchymal tumors”: expanding the immunohistochemical profile and molecular spectrum of a recently described entity with the proposed revision of nomenclature 2022(3)

NR1D1::MAML1 epithelioid and spindle cell sarcoma mimicking pseudomyogenic hemangioendothelioma in core biopsy: A case report and review of the literature 2023(1)